| Name | Title | Contact Details |
|---|
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.
Amerigen Pharmaceuticals Inc is a East Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adamis Pharmaceuticals Corporation is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.